Xiujuan Qu
YOU?
Author Swipe
View article: SIM0708, an antibody-drug conjugate (ADC) with half-life extended anti-IL-4 receptor a (IL-4Ra) antibody and glucocorticoid receptor modulator exhibits superior efficacy treating inflammatory diseases 4657
SIM0708, an antibody-drug conjugate (ADC) with half-life extended anti-IL-4 receptor a (IL-4Ra) antibody and glucocorticoid receptor modulator exhibits superior efficacy treating inflammatory diseases 4657 Open
Description Background IL-4Ra plays an important role in the pathogenesis of inflammatory diseases including atopic dermatitis, asthma, COPD, etc. Glucocorticoids (GCs) are efficacious drugs commonly used for treating inflammatory diseases…
View article: Case Report: Is the isolated bone change in advanced colorectal cancer necessarily malignant metastasis?
Case Report: Is the isolated bone change in advanced colorectal cancer necessarily malignant metastasis? Open
Background Radiation osteitis (RO) is a bone-related complication following radiotherapy (RT), often characterized by atypical imaging features. It is challenging to distinguish RO from early bone metastasis (BM), potentially leading to in…
View article: CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial
CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial Open
Aberrant expression of claudin18.2 (CLDN18.2) has frequently been observed in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma, making it a promising therapeutic target for this aggressive cancer. While a monoclonal antibody ta…
View article: Targeting Intratumoral Bacteria for Cancer Treatment
Targeting Intratumoral Bacteria for Cancer Treatment Open
Intratumoral bacteria have emerged as critical modulators of cancer biology and therapeutic outcomes. Substantial evidence has demonstrated that tumors harbor diverse bacterial communities capable of interacting with both cancer cells and …
View article: Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial Open
View article: Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial Open
View article: Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial Open
HA121-28, a promising multikinase inhibitor, mainly targets rearranged during transfection (RET) fusions and selectively targets vascular endothelial growth factor receptor-2, endothelial growth factor receptor, and fibroblast growth facto…
View article: ANXA10 sensitizes microsatellite instability-high colorectal cancer to anti-PD-1 immunotherapy via assembly of HLA-DR dimers by regulating CD74
ANXA10 sensitizes microsatellite instability-high colorectal cancer to anti-PD-1 immunotherapy via assembly of HLA-DR dimers by regulating CD74 Open
View article: Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study
Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study Open
View article: Phase Ib/II Study of the CEND-1 (Targeting αV-Integrin and Neuropilin-1) with nab-Paclitaxel/Gemcitabine in First-Line Treatment of Metastatic Pancreatic Cancer
Phase Ib/II Study of the CEND-1 (Targeting αV-Integrin and Neuropilin-1) with nab-Paclitaxel/Gemcitabine in First-Line Treatment of Metastatic Pancreatic Cancer Open
View article: A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive heavily pretreated solid tumors: results from a phase Ia/Ib first-in-human, open-label, single center study
A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive heavily pretreated solid tumors: results from a phase Ia/Ib first-in-human, open-label, single center study Open
Background IAH0968 is an afucosylated anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody which improved the activity of antibody-dependent cellular cytotoxicity (ADCC) and superior anti-tumor efficacy. Methods To determine …
View article: Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis
Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis Open
Background The first-line treatment for advanced hepatocellular carcinoma has evolved significantly. This study aimed to identify the most beneficial regimen. Methods A systematic search was conducted from July 2012 to August 2024 across t…
View article: Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study
Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study Open
ClinicalTrials.gov identifier: NCT03053167, registration date was 14/2/2017.
View article: Prognostic heterogeneity of Ki67 in non‐small cell lung cancer: A comprehensive reappraisal on immunohistochemistry and transcriptional data
Prognostic heterogeneity of Ki67 in non‐small cell lung cancer: A comprehensive reappraisal on immunohistochemistry and transcriptional data Open
In the present study, the debatable prognostic value of Ki67 in patients with non‐small cell lung cancer (NSCLC) was attributed to the heterogeneity between lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC). Based on meta‐analy…
View article: Consensus statement on extracellular vesicles in liquid biopsy for advancing laboratory medicine
Consensus statement on extracellular vesicles in liquid biopsy for advancing laboratory medicine Open
Extracellular vesicles (EVs) represent a diverse class of nanoscale membrane vesicles actively released by cells. These EVs can be further subdivided into categories like exosomes and microvesicles, based on their origins, sizes, and physi…
View article: TKI for immunotherapy refractory in MSI-H colorectal cancer: a case report
TKI for immunotherapy refractory in MSI-H colorectal cancer: a case report Open
Some of metastatic colorectal cancer (CRC) patients with MSI-H status do not have robust and lasting benefit from mono-immunotherapy, how to extend the benefit of immunotherapy for those patients is still an urgent problem to be solved. He…
View article: Is the isolated bone change in advanced colorectal cancer a necessarily malignant metastasis? A case series
Is the isolated bone change in advanced colorectal cancer a necessarily malignant metastasis? A case series Open
Radiation osteitis (RO) is one of the bone complications arising after radiotherapy (RT). Limited to atypical manifestation in imaging. RO is difficult to diagnose, and sometimes, it could be considered as an early bone metastasis (BM), re…
View article: Neutrophils in the tumor microenvironment: role in tumor progression and potential targeted therapeutic strategy
Neutrophils in the tumor microenvironment: role in tumor progression and potential targeted therapeutic strategy Open
Neutrophils are known as the body's first line of defense against invading pathogens, which are the most abundant bone-marrow-derived innate immune cells accounting for 50%-70% of all white blood cells in human peripheral blood. With in-de…
View article: Genetic feature diversity of KRAS-mutated colorectal cancer and the negative association of DNA mismatch repair deficiency relevant mutational signatures with prognosis
Genetic feature diversity of KRAS-mutated colorectal cancer and the negative association of DNA mismatch repair deficiency relevant mutational signatures with prognosis Open
View article: Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multicenter, Phase II study
Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multicenter, Phase II study Open
Background Colorectal cancer is the third most common cancer and the second leading cause of cancer death. There are limited therapeutic options for the treatment of locally advanced or metastatic colorectal cancers which fail first-line c…
View article: Case report: A case of rare metastasis of gastric cancer to the axillary lymph node metastasis treated with combination immunotherapy
Case report: A case of rare metastasis of gastric cancer to the axillary lymph node metastasis treated with combination immunotherapy Open
Lymph node (LN) metastasis is a common mode of metastasis in advanced gastric cancer (GC), while axillary LN metastasis infrequently occurs in GC. There are few reports on this rare type of metastasis – especially its clinicopathological f…
View article: Correction: Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept
Correction: Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept Open
View article: Unveiling the role of KRAS in tumor immune microenvironment
Unveiling the role of KRAS in tumor immune microenvironment Open
Kirsten rats sarcoma viral oncogene (KRAS), the first discovered human oncogene, has long been recognized as "undruggable". KRAS mutations frequently occur in multiple human cancers including non-small cell lung cancer(NSCLC), colorectal c…
View article: Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept
Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept Open
View article: Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China
Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China Open
View article: Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR-positive and HER2-negative advanced breast cancer: results from a phase Ib study
Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR-positive and HER2-negative advanced breast cancer: results from a phase Ib study Open
Background: Dalpiciclib is a novel cyclin-dependent kinase 4/6 inhibitor which showed tolerability and preliminary efficacy as monotherapy for pretreated advanced breast cancer (BC). Objectives: To further assess dalpiciclib with endocrine…
View article: The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023 Open
The 2023 update of the Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for Gastric Cancer focuses on standardizing cancer diagnosis and treatment in China, reflecting the latest advancements in evidence‐based medicine, heal…
View article: PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis
PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis Open
Background The combinations of PD-1 inhibitors with paclitaxel/cisplatinum (PD-1 + TP) and fluoropyrimidine/cisplatinum (PD-1 + FP) both have been shown to improve overall survival (OS) and progression-free survival (PFS) in patients with …
View article: 691 First-in-human trial of novel HBsAg-specific TCR T cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma
691 First-in-human trial of novel HBsAg-specific TCR T cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma Open
Background Hepatitis B virus (HBV) infection accounts for 75–80% of virus-associated Hepatocellular carcinoma (HCC). HBV DNA integration into the host cell genome produces viral antigens and can lead to tumorigenesis, which can be effectiv…
View article: PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis
PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis Open
Background The combination of PD-1 inhibitors with paclitaxel/cisplatinum (PD-1 + TP) and fluoropyrimidine/cisplatinum (PD-1 + FP) both have been shown to improve overall survival (OS) and progression-free survival (PFS) in patients with p…